19:07 , Feb 22, 2017 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Mouse studies suggest inhibiting CD6 could help treat MS. In an experimental autoimmune encephalomyelitis (EAE) mouse model of MS, CD6 knockout decreased clinical signs of encephalomyelitis and T cell infiltration in the...
07:00 , Sep 16, 2013 |  BioCentury  |  Strategy

Alzumab's (re)mission statement

Biocon Ltd. is betting the long remission time and reduced opportunistic infections associated with its Alzumab itolizumab will pull doctors away from biologics with better efficacy in psoriasis. The company has long maintained that the first-in-class...
07:00 , Aug 19, 2013 |  BC Week In Review  |  Company News

Biocon sales and marketing update

Biocon launched Alzumab itolizumab in India to treat chronic plaque psoriasis. Biocon said the price for a 25 mg/5 mL vial of Alzumab is Rs7,950 ($131) and that the recommended dose is 1.6 mg/kg,...
07:00 , Apr 1, 2013 |  BioCentury  |  Finance

1Q Stock Wrap-Up: Out fast at opening bell

For the second year in a row, biotech put together a strong showing in the first quarter with all market segments gaining ground. The sector was led by mid-caps, which closed up 16%. Large caps were...
08:00 , Jan 14, 2013 |  BC Week In Review  |  Clinical News

Alzumab itolizumab regulatory update

Biocon said India's Drugs Controller General of India (DCGI) approved Alzumab itolizumab to treat chronic plaque psoriasis. The company plans to launch the humanized IgG1 mAb that inhibits CD6 in the country later this...
08:00 , Jan 14, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Biocon Ltd. (NSE:BIOCON; BSE:BIOCON) was off Rs9.10 to Rs282.45 last week on India's National Stock Exchange after the Drugs Controller General of India approved Alzumab itolizumab to treat chronic plaque psoriasis. The company plans...
01:24 , Jan 9, 2013 |  BC Extra  |  Company News

India approves Biocon's anti-CD6 mAb

Biocon Ltd. (NSE:BIOCON; BSE:BIOCON) said India's Drugs Controller General of India (DCGI) approved Alzumab itolizumab to treat chronic plaque psoriasis. The company plans to launch the humanized IgG1 mAb that inhibits CD6 in the country...
08:00 , Jan 23, 2012 |  BioCentury  |  Product Development

Biocon's MOA bet

Though a Phase III trial of Biocon Ltd.'s anti-CD6 mAb itolizumab did not show as much efficacy as other biologics in psoriasis, the biotech thinks lower infection rates could differentiate the mAb from the anti-TNFs. Biocon...
08:00 , Jan 16, 2012 |  BC Week In Review  |  Clinical News

Itolizumab: Interim Phase III data

Interim data from the double-blind, placebo-controlled, Indian Phase III TREAT-PLAQ trial in 225 patients with moderate to severe plaque psoriasis showed that 0.4 and 1.6 mg/kg IV itolizumab every 2 weeks for 12 weeks met...
08:00 , Jan 16, 2012 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Amylin Pharmaceuticals Inc. (NASDAQ:AMLN) gained $0.77 to $11.79 last week after the U.K.'s NICE issued a final appraisal determination backing use of once-weekly Bydureon exenatide to treat Type II diabetes in triple and dual therapy...